KeyBanc Capital Markets initiated coverage on Recursion Pharmaceuticals with a new price target

9/16/22 7:27:04 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

KeyBanc Capital Markets initiated coverage of Recursion Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RXRX

Date	Price Target	Rating	Analyst
5/22/2023	$8.00	Equal-Weight	Morgan Stanley
3/16/2023	$17.00	Buy	Needham
9/16/2022	$20.00	Overweight	KeyBanc Capital Markets
4/18/2022	$10.00	Buy → Neutral	BofA Securities
3/4/2022	$32.00 → $10.00	Outperform → Market Perform	SVB Leerink
12/8/2021	$30.00 → $32.00	Outperform	SVB Leerink
9/21/2021	$37.00	Buy	Berenberg
8/16/2021	$33.00 → $30.00	Outperform	SVB Leerink